Therapeutic control of viral infections: chemotherapy, interferon and gamma globulin.
D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use; D002644:Chickenpox / Q000628:therapy; D003561:Cytarabine / Q000627:therapeutic use; D006525:Hepatitis, Viral, Human / Q000628:therapy; D006561:Herpes Simplex / Q000628:therapy; D006562:Herpes Zoster / Q000628:therapy; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007542:Inosine Pranobex / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D008457:Measles / Q000628:therapy; D009107:Mumps / Q000628:therapy; D010746:Phosphonoacetic Acid / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D012409:Rubella / Q000628:therapy; D014611:Vaccination / Q000009:adverse effects; D014616:Vaccinia virus / Q000276:immunology; D014740:Vidarabine / Q000627:therapeutic use; D014777:Virus Diseases / Q000188:drug therapy* / Q000628:therapy; D005719:gamma-Globulins / Q000627:therapeutic use*
D001562:Benzimidazoles; D005719:gamma-Globulins; D003561:Cytarabine; D012254:Ribavirin; D007372:Interferons; D000547:Amantadine; D014740:Vidarabine; D007065:Idoxuridine; D010746:Phosphonoacetic Acid; D012293:Rifampin; D007542:Inosine Pranobex